
Journal of the American College of Cardiology, Journal Year: 2023, Volume and Issue: 81(24), P. 2358 - 2360
Published: June 1, 2023
Language: Английский
Journal of the American College of Cardiology, Journal Year: 2023, Volume and Issue: 81(24), P. 2358 - 2360
Published: June 1, 2023
Language: Английский
The Journal of Heart and Lung Transplantation, Journal Year: 2024, Volume and Issue: 43(10), P. 1529 - 1628.e54
Published: Aug. 8, 2024
Language: Английский
Citations
21Journal of Hepatology, Journal Year: 2024, Volume and Issue: 81(6), P. 1040 - 1086
Published: Oct. 31, 2024
Language: Английский
Citations
18New England Journal of Medicine, Journal Year: 2024, Volume and Issue: 391(19), P. 1822 - 1836
Published: Nov. 13, 2024
Lung transplantation has evolved from an experimental to a standard treatment. The authors review recent developments and future opportunities in the delivery of this potentially life-transforming therapy.
Language: Английский
Citations
8Zeitschrift für Gastroenterologie, Journal Year: 2024, Volume and Issue: 62(09), P. 1397 - 1573
Published: Sept. 1, 2024
Citations
7Current Opinion in Organ Transplantation, Journal Year: 2023, Volume and Issue: 28(5), P. 384 - 390
Published: Aug. 8, 2023
The potential for transmission of donor-derived infections (DDIs) is impossible to eliminate, but a thoughtful and systematic approach donor evaluation can mitigate the risk. Prevention key issue clinicians must maintain high index suspicion remain vigilant in staying up date on emerging infections. COVID-19 Monkeypox have represented new challenge infectious disease screening recommendations been evolving, as knowledge field has grown. Additional considerations pretransplant deceased include testing neglected endemic diseases such strongyloidiasis HTLV 1/2. Molecular diagnostic tests improved awareness pathogenicity mollicutes fungi setting DDIs. aim this review provide an update most recent literature DDI with special focus these hot topics.
Language: Английский
Citations
10Pediatric Transplantation, Journal Year: 2025, Volume and Issue: 29(4)
Published: May 7, 2025
ABSTRACT Introduction Pediatric Infectious Disease (PID) clinicians involved in solid organ transplantation often assess infection risk and mitigation strategies for donor offers. While some guidance is available, real‐life practice patterns have not been previously described. Methods We surveyed PID about acceptance associated posttransplantation interventions using 12 fictitious pediatric case scenarios through 3 PID‐specific listservs. Descriptive statistics were employed. Results 48 (71.6%) of 67 ID respondents offer assessment. Agreement was strong (> 80%) to accept (syphilis, severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2], MRSA, E. coli , TB [liver], rhino/enterovirus) or decline (undifferentiated encephalitis, [lung]) organs from these cases, while there less agreement cases with coccidioidomycosis, Chagas disease, multi‐drug‐resistant Acinetobacter baumannii influenza. Less present posttransplant monitoring antimicrobial administration. Practice varied testing treatment donors SARS‐CoV‐2 positive test, MRSA bacteremia, disease. Conclusions For many scenarios, high; however, improved education based on currently available recommendations may enhance decision‐making. The variability management highlights educational research opportunities optimize limit the impact donor‐derived infections recipients.
Language: Английский
Citations
0Clinical Journal of the American Society of Nephrology, Journal Year: 2023, Volume and Issue: 18(11), P. 1466 - 1475
Published: Aug. 14, 2023
Acceptable post-transplant outcomes were reported in kidney transplant recipients from donors with coronavirus disease 2019 (COVID-19); however, there are no comparative studies well-matched controls.
Language: Английский
Citations
6Transplant Infectious Disease, Journal Year: 2023, Volume and Issue: 25(6)
Published: Nov. 8, 2023
Donor-derived infections in solid organ transplantation can be prevented by risk stratification of donors based on available information, and inquiries surrounding possible or diagnosed infection are common questions posed to transplant infectious disease subspecialists. This article outlines the five key steps addressing a donor call from team systematic approach, focusing recipient-specific factors, transmissibility treatment infections, likelihood patient's future offers mortality remaining waitlist. These principles then applied cases, which we review takeaway points supporting literature. cases used as resource for teaching with trainees.
Language: Английский
Citations
6Transplant Infectious Disease, Journal Year: 2023, Volume and Issue: 25(5)
Published: Aug. 16, 2023
Since November 2020, Italy was the first country to carry out a protocol and use liver from COVID-19 donors. We aimed evaluate medium-term outcome of patients who underwent transplant (LT) with those grafts.We consecutively enrolled 283 LT 2020 December 2022 in our Center (follow-up 468 days). Twenty-five (8.8%, study population) received graft donors previous (4%) or active (96%) SARS-CoV-2 infection, 258/283 (91.2%, control group) COVID-19-negative SARS-CoV-2-RNA tested on tissue their recipients weekly evaluation nasal swabs for month after LT.One-year 2-year patient survival 88.5% group versus 94.5% 93.5% group, respectively (p = .531). In population there no evidence donor-recipient virus transmission, but three (12%) (vs. 7 [2.7%] p .048) developed hepatic artery thrombosis (HAT): they were negative at 1/3 grafts positive tissue. donor independently associated HAT (odds ratio (OR) 4.85, 95% confidence interval (CI) 1.10-19.15; .037). By comparing acute rejection biliary complication rates not significantly different (16% vs. 8.1%, .26; 16% 16.3% .99, respectively).Our 1-year results strategy including favorable. only higher rate transplanted compared group.
Language: Английский
Citations
5Frontiers in Pediatrics, Journal Year: 2023, Volume and Issue: 11
Published: Oct. 4, 2023
Prevention of donor-derived disease among pediatric solid organ transplant recipients requires judicious risk-benefit assessment. Comprehensive guidelines outline specific donor risk factors and post-transplant monitoring strategies to prevent mitigate transmission HIV, hepatitis B, C. However, elimination unanticipated infections remains challenging. The objectives this review are (1) define anticipated vs. events in recipients; (2) discuss presentations that confer greater transmission; (3) develop a matrix for consideration acceptance; (4) limitations future directions screening. Although confers inherent infection transmission, the significant may be mitigated by comprehensive approach including assessment, recipient need, monitoring, early intervention.
Language: Английский
Citations
5